Need a report that reflects how COVID-19 has impacted this market and its growth?
The European insulin infusion pump market is expected to register a CAGR greater than 4% over the forecast period (2022-2027).
The COVID-19 pandemic has had a significant impact on the market studied. Type-1 diabetes patients have been more affected during the pandemic since people with diabetes have weak immune systems. People with diabetes are also more likely to face serious complications than normal people. The estimated cost per hospital admission during the first wave of COVID-19 in Europe ranged from EUR 25,018 for Type 2 diabetes patients with good glycemic control to EUR 57,244 for Type 1 diabetes patients with poor glycemic control. This reflects a higher risk of intensive care and ventilator support and a longer hospital stay. The estimated cost for patients without diabetes was EUR 16,993. The estimated total direct expenditure for secondary care for COVID-19 in Europe was EUR 13.9 billion. Therefore, diabetes treatment accounted for 23.5% of the total expenditures.
An insulin pump (also known as continuous subcutaneous insulin therapy) is a medical device used for the administration of insulin in the treatment of diabetes. Insulin pumps make it possible to deliver continuous infusion amounts of insulin at regular intervals. This is predicted to result in long-term cost savings relative to multiple daily injections. A conventional insulin pump includes the pump (including controls, a processing module, and batteries), a disposable reservoir for insulin (inside the pump), and a disposable infusion set, including a cannula for subcutaneous (under the skin) insertion and a tubing system to connect the insulin reservoir to the cannula. The configuration of the device may vary depending on the design. However, the application of infusion pumps across the world is increasing significantly.
Scope of the Report
The European insulin infusion pump market is expected to register a CAGR greater than 4% over the forecast period (2022-2027). The market is segmented by component (pump devices, infusion sets, and reservoirs) and geography (France, Germany, Italy, Spain, United Kingdom, Russia, and Rest of Europe). The report offers the market sizes and forecasts in terms of value (USD million) and volume for the above segments.
|By Insulin Infusion Pump (Value and Volume, 2016 - 2027)|
|Insulin Pump Devices|
|Insulin Infusion Sets|
Key Market Trends
Insulin Pump Monitors Hold Largest Market Share
The countries in Europe are facing a high burden of diabetes expenditure. According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. According to the same source, 21,600 children are added to the Type-1 diabetic population every year. These figures indicate that approximately 9% of the total healthcare expenditure in Europe is spent on diabetes. For patients relying on insulin pumps or multiple daily injections (MDI), CGM systems are an effective tool. They help in the improvement of glycemic balance without aggravating the danger of severe hypoglycemia.
In Europe, a variety of insulin pumps are available. Conventional insulin pumps have an insulin reservoir (or container) and a pumping mechanism attached to the body with tubing and an infusion set. Other insulin patch pumps are worn directly on the body and have a reservoir, pumping mechanism, and infusion set inside a small case. Patch pumps are controlled wirelessly by a separate device that allows the programming of insulin delivery from the patch. Most insurance companies in Europe cover insulin pump therapy with variable out-of-pocket expenses.
The technology associated with insulin pumps combines glucose monitoring using CGM with advanced algorithms to predict low glucose and suspend insulin delivery. The technological innovation in the insulin pumps market is likely to drive the market during the forecast period.
To understand key trends, Download Sample Report
Germany Holds the Highest Market Share
A study conducted in July 2020 in Germany found a significant increase in diabetic ketoacidosis and severe ketoacidosis in diabetes diagnosis in children and adolescents during the COVID-19 pandemic. The underlying causes for this increase may be multifactorial and reflect reduced medical services, fear of approaching the healthcare system, and other complex psychosocial factors. The German Center for Diabetes Research (DZD) conducts extensive scientific research to develop effective prevention and treatment measures to prevent the emergence or progression of diabetes. Around 11% of the people living in Germany have private health insurance. Only people who fulfill certain criteria can have private health insurance. For example, the gross income of the person seeking insurance must be above a certain threshold for at least one year. The developments in the insulin infusion pump reimbursement field are expected to bolster the adoption of insulin infusion pumps in Germany.
To understand geography trends, Download Sample Report
The new technologies in insulin infusion pump devices have driven the market studied. Animas had to exit the insulin pump market owing to the rising competition. Medtronic is the market leader and is expected to maintain its position during the forecast period.
- In May 2021, Medtronic obtained European approvals for its Guardian 4 sensor. The Guardian 4 sensor can be either used as a standalone continuous glucose monitor or integrated into Medtronic’s insulin pumps and pens to add real-time glucose monitoring alongside insulin tracking.
- In April 2021, Medtronic unveiled an infusion set for diabetes in select countries in Europe. The extended infusion set was the first set that could be worn to deliver insulin for up to seven days.
Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Insulin Infusion Pump (Value and Volume, 2016 - 2027)
5.1.1 Insulin Pump Devices
5.1.2 Insulin Infusion Sets
5.2.1 France (Value and Volume, 2016 - 2027)
126.96.36.199 Insulin Pump Devices
188.8.131.52 Infusion Sets
5.2.2 Germany (Value and Volume, 2016 - 2027)
184.108.40.206 Insulin Pump Devices
220.127.116.11 Infusion Sets
5.2.3 Italy (Value and Volume, 2016 - 2027)
18.104.22.168 Insulin Pump Devices
22.214.171.124 Infusion Sets
5.2.4 Spain (Value and Volume, 2016 - 2027)
126.96.36.199 Insulin Pump Devices
188.8.131.52 Infusion Sets
5.2.5 United Kingdom (Value and Volume, 2016 - 2027)
184.108.40.206 Insulin Pump Devices
220.127.116.11 Infusion Sets
5.2.6 Russia (Value and Volume, 2016 - 2027)
18.104.22.168 Insulin Pump Devices
22.214.171.124 Infusion Sets
5.2.7 Rest of Europe (Value and Volume, 2016 - 2027)
126.96.36.199 Insulin Pump Devices
188.8.131.52 Infusion Sets
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population (2016 - 2027)
6.2 Type-2 Diabetes Population (2016 - 2027)
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.2 COMPANY SHARE ANALYSIS
7.2.4 Other Companies
8. MARKET OPPORTUNITES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Europe Insulin Infusion Pumps Market market is studied from 2016 - 2027.
What is the growth rate of Europe Insulin Infusion Pumps Market?
The Europe Insulin Infusion Pumps Market is growing at a CAGR of >4% over the next 5 years.
What is Europe Insulin Infusion Pumps Market size in 2016?
The Europe Insulin Infusion Pumps Market is valued at 513 Million USD in 2016.
What is Europe Insulin Infusion Pumps Market size in 2027?
The Europe Insulin Infusion Pumps Market is valued at 635 Million USD in 2027.
Who are the key players in Europe Insulin Infusion Pumps Market?
Medtronic, Roche, Ypsomed, Insulet are the major companies operating in Europe Insulin Infusion Pumps Market.